Racura Oncology Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 4

Employees

  • Stock Symbol
  • RAC

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.07
  • (As of Friday Closing)

Racura Oncology General Information

Description

Racura Oncology Ltd is a Phase 3 clinical-stage biopharmaceutical company with a dedicated mission to silence cancer. The company's clinical programs include the Phase 3 EMILI trial in acute myeloid leukaemia, the Phase 1a/b HARNESS trial in combination with osimertinib for EGFR-mutated non-small cell lung cancer, and the Phase 1a/b CPACS trial in combination with doxorubicin, where it aims to deliver both anthracycline cardioprotection and enhanced anticancer activity. The company operated in two segments, being research into an oncology drug, RC220, and the manufacturing and distribution of the drug for clinical trials.

Contact Information

Formerly Known As
Coronado Resources, Race Oncology
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Level 36, Gateway Tower
  • 1 Macquarie Place
  • Sydney, New South Wales 2000
  • Australia
+61 (02)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
ASX
Vertical(s)
Corporate Office
  • Level 36, Gateway Tower
  • 1 Macquarie Place
  • Sydney, New South Wales 2000
  • Australia
+61 (02)

Racura Oncology Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Racura Oncology Stock Performance

As of 20-Nov-2026, Racura Oncology’s stock price is $1.07. Its current market cap is $211M with 196M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.07 $1.06 $0.98 - $2.58 $211M 196M 88.9K

Racura Oncology Financials Summary

As of 30-Sep-2026, Racura Oncology has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 235,010 285,138 121,080 197,557
EBITDA (7,736) (3,426) (9,418)
Net Income (7,512) (3,097) (9,056)
Total Assets 26,213 11,424 13,521
Total Debt 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Racura Oncology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Racura Oncology‘s full profile, request access.

Request a free trial

Racura Oncology Patents

Racura Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024903211-A0 Pharmaceutical compositions suitable for intravenous administration Pending 04-Oct-2024
WO-2026073303-A1 Pharmaceutical compositions suitable for intravenous administration Pending 04-Oct-2024
AU-2022901827-A0 Method of cardioprotection Inactive 30-Jun-2022
AU-2022901791-A0 Treatment of melanoma Inactive 27-Jun-2022
AU-2022901702-A0 Treatment of melanoma Inactive 22-Jun-2022
To view Racura Oncology’s complete patent history, request access »

Racura Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Racura Oncology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Racura Oncology‘s full profile, request access.

Request a free trial

Racura Oncology Investments & Acquisitions (2)

Racura Oncology’s most recent deal was a Joint Venture with Race Immunotherapeutics. The deal was made on 10-Jul-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Race Immunotherapeutics 10-Jul-2017 Joint Venture Drug Discovery
Update Pharma 01-Jul-2016 Merger/Acquisition Drug Discovery
To view Racura Oncology’s complete investments and acquisitions history, request access »

Racura Oncology ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Racura Oncology’s complete esg history, request access »

Racura Oncology FAQs

  • When was Racura Oncology founded?

    Racura Oncology was founded in 2011.

  • Where is Racura Oncology headquartered?

    Racura Oncology is headquartered in Sydney, Australia.

  • What is the size of Racura Oncology?

    Racura Oncology has 4 total employees.

  • What industry is Racura Oncology in?

    Racura Oncology’s primary industry is Biotechnology.

  • Is Racura Oncology a private or public company?

    Racura Oncology is a Public company.

  • What is Racura Oncology’s stock symbol?

    The ticker symbol for Racura Oncology is RAC.

  • What is the current stock price of Racura Oncology?

    As of 20-Nov-2026 the stock price of Racura Oncology is $1.07.

  • What is the current market cap of Racura Oncology?

    The current market capitalization of Racura Oncology is $211M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process